Farmas, UAB - financials and debts

Company age: 9 y. 9 mo.

Update

Farmas - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 4,169,849 5,484,141 5,701,251 8,449,210 10,691,313 18,875,003 20,759,709 15,669,399
Profit before tax 5,741 - 121,785 13,755 689,334 2,605,642 6,330,279 1,731,521
Net profit 4,880 39,970 103,517 11,692 585,934 2,213,537 5,377,687 1,501,068
Equity 16,507 56,477 159,994 171,686 757,620 2,971,157 8,348,844 9,849,912
Liabilities 735,879 263,376 850,529 1,311,394 1,017,969 4,067,771 1,095,174 2,747,212
Non-current assets 0 0 0 0 152,903 43,136 228,253 58,139
Current assets 752,386 319,853 1,010,523 1,483,080 1,622,686 6,995,792 9,215,765 12,538,985
Total assets 752,386 319,853 1,010,523 1,483,080 1,775,589 7,038,928 9,444,018 12,597,124
Taxes paid
STI taxes - - - - - 64,153 825,286 1,545,511
Social insurance contributions - - - - - 34,899 61,687 11,040
Financial indicators
Revenue change y/y +170.4% +31.5% +4.0% +48.2% +26.5% +76.5% +10.0% -24.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 0.6% 12.5% 10.2% 0.8% 33.0% 31.4% 56.9% 11.9%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 29.6% 70.8% 64.7% 6.8% 77.3% 74.5% 64.4% 15.2%
Profit margin Net profit margin. Shows the overall profitability of the company. 0.1% 0.7% 1.8% 0.1% 5.5% 11.7% 25.9% 9.6%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 0.1% - 2.1% 0.2% 6.4% 13.8% 30.5% 11.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 44.6 4.7 5.3 7.6 1.3 1.4 0.1 0.3
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 4,169,849 5,484,141 5,701,251 2,982,109 2,789,062 4,718,751 4,370,465 5,223,133

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Farmas - Social security debts

From To Debt, €
2026-02-18 2026-02-19 10590.87
2025-11-18 2025-11-18 4096.07
2025-04-16 2025-04-16 10650.61
2025-02-18 2025-03-12 62.76

Farmas - VMI tax arrears

From To Overdue, €
2026-02-18 2026-02-21 975.38
2026-01-13 2026-01-13 3346.56
2025-11-12 2025-11-12 10318.59
2025-11-09 2025-11-11 9200.29
2025-11-08 2025-11-08 9749.29
2025-10-11 2025-10-18 6159.48
2025-07-24 2025-07-26 85.09
2025-07-20 2025-07-23 3387.84
2025-07-19 2025-07-19 1482.18
2025-07-15 2025-07-18 392105.0
2025-07-11 2025-07-14 400727.72
2025-07-10 2025-07-10 8622.72
2025-07-02 2025-07-09 40.48
2025-07-01 2025-07-01 85617.45
2025-06-30 2025-06-30 85548.36
2025-06-28 2025-06-29 85502.28
2025-06-27 2025-06-27 85505.97
2025-06-26 2025-06-26 87018.97
2025-06-22 2025-06-25 86901.77
2025-06-21 2025-06-21 96066.08
2025-06-20 2025-06-20 96066.1
2025-06-19 2025-06-19 95988.34
2025-04-24 2025-04-26 74.7
2025-04-12 2025-04-16 9236.29
2025-03-31 2025-03-31 105.62
2025-03-27 2025-03-30 107.06
2025-03-26 2025-03-26 113.99
2025-03-20 2025-03-24 113168.27
2025-03-15 2025-03-19 15142.27
2025-01-28 2025-01-29 19740.87

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Farmas, UAB (code 304430002) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €15.67M and net profit of €1.50M, with a profit margin of 9.6%. Revenue declined by 24.5% year on year, after reaching €20.76M in 2024; in 2023, revenue was €18.88M. Profitability followed the same pattern, rising from €2.21M in 2023 to €5.38M in 2024 before easing to €1.50M in 2025. Despite the weaker year, the company remained profitable and recorded a solid return profile, with ROE of 15.2% and ROA of 11.9% in 2025. The balance sheet strengthened further, with total assets increasing to €12.60M and equity to €9.85M, while liabilities stood at €2.75M. The equity ratio was 78.2% and debt-to-equity 0.28, indicating a conservative capital structure. Asset turnover was 1.24x. Revenue per employee was €5.22M and profit per employee €500.4K in 2025.